https://www.prognyx.com/blog/selinexor-s-tp53-wild-type-bet-misses-xport-ec-042-returns-a-hazard-ratio-of-0-7Prognyxen2026-08-01Selinexor's TP53 wild-type bet misses: XPORT-EC-042 returns a hazard ratio of 0.76 (95% CI 0.51–1.12), double the SIENDO subgroup's 0.38 https://www.prognyx.com/blog/j-j-s-reported-785m-upfront-for-sail-comes-with-a-2-58b-option-on-in-vivo-car-tPrognyxen2026-07-30J J's reported $785M upfront for Sail comes with a $2.58B option on in vivo CAR-T — and almost no clinical record to price it against